Un­der-the-radar Chi­nese biotech scores $47M up­front in se­cre­tive Mer­ck deal around can­cer drug

During his most recent investor call, Merck CEO Rob Davis promised to be “appropriately aggressive in pursuing compelling external innovation.” But as it turns out, that doesn’t necessarily mean they would be loud about it.

China’s Kelun Pharmaceutical said the pharma giant has licensed a certain “large molecule” cancer drug candidate from its biotech subsidiary Sichuan Kelun-Biotech.

Read the source article at endpts.com
2022-05-18 10:48:27